sector medic suppli devic
ad guggenheim best idea list
messag launch coverag june thesi improv
top line growth would lead rise street estim multipl expans
process begun play expect acceler impact recent
new product launch reflect compani result start soon
still trade mani higher growth peer believ remain
well posit outperform rais pt
ad guggenheim best idea list replac ew
revalu stori yet continu see abbott premium growth asset
within large-cap med-tech group model call compani gener
top bottom line growth vs sector averag roughli
respect acceler began pick steam
comp eas impact recent new product approv ellips mri libr confirm
heartmat etc begin reflect compani result yet despit view
highli visibl array growth driver head street slow
embrac idea abbott top line grower revenu estim
roughli consensu compani deliv opportun
front expect improv sentiment rise street estim drive
multipl expans stock posit abbott outperform come year
st jude turnaround remain heart abbott growth acceler
met mix review announc april believ st
jude acquisit strateg sound well-tim although busi
struggl time st jude averag organ sale growth
attract end market mix compel pipelin made logic turnaround candid
abbott foresight front appear pay underli growth st
jude improv math pois jump
big piec acceler franchis expect shift
declin growth compani anniversari
recal leverag recent ellips mri approv reengag account
priorit mri-condit label manag continu expect second mri
approv rest high power product line immin forecast assum
abbott captur world-wide market share would repres
strong perform would note repres fraction nearli
share st jude lost due qualiti issu hole product portfolio
outsid abbott devic franchis alreadi perform high
level estim st jude ex-crm growth averag past six
quarter driven strong gain neuromodul electrophysiolog two busi
collect bigger compani rhythm manag franchis
expect neuro momentum moder go forward comp get tougher
remain grower buoy strong underli market growth
continu db share gain wake st jude entri market
meanwhil expect ep segment get boost launch confirm
implant cardiac monitor octob fda approv estim icm market
top grow low doubl digit abbott posit
chip away success reveal linq franchis elsewher heart failur
structur heart segment continu deliv solid growth back
recent heartmat fda approv dt label expans expect continu
momentum mitraclip
continu page
page analyst certif import disclosur
final continu see libr disrupt new entrant blood
glucos monitor market follow domest launch month ago
system avail number nation retail rite aid
walgreen dme patient need pay pocket
reimburs establish believ low up-front cost
receiv per sensor encourag trial abbott also offer system
free charg qualifi user may take compani
month build critic mass reimburs front continu see libr
superior econom someth payer eventu embrac similar
experi europ model call abbott gener libr sale
ramp meanwhil despit success date
revenu track top believ libr still substanti growth potenti
intern well septemb abbott receiv reimburs approv
japan uk open two larg new market opportun first time
posit product continu strong growth ou
fact outsid real weak spot abbott medic devic line-up
today vascular franchis admittedli cautiou head
outlook compani drug-elut stent franchis potenti get
challeng multipl front includ china continu expect
meaning price cut announc near futur japan
undergo biannual price cut april meanwhil although dont expect
cardin get much traction medinol recent approv elunir stent even modest
share gain would repres increment headwind incumb player
combin stronger competit posit follow may launch
resolut onyx paint rather difficult pictur abbott de franchis although
manag optimist launch next-gen xienc sierra stent
fda approv off-set headwind model call
compani de sale fall result cc declin vascular
segment overal repres somewhat fli ointment good news
abbott enough trend right direct within devic busi
drive acceler growth
beyond devic see sever growth catalyst throughout rest
abbott portfolio well chief among pediatr nutrit segment
pois swing headwind tailwind new regul go effect china
estim abbott overal chines nutrit busi declin roughli
today driven primarili flood cheap infant formula
inventori brought market wake govern decis impos
stricter rule qualiti number brand produc one manufactur
facil regul final went effect januari posit abbott take
share smaller competitor exit market assum benefit
partial off-set moder pediatr growth track grow
unsustain net effect still meaning acceler
busi overal model call world-wide pediatr nutrit sale rise
gain elsewher continu roll-out
alin platform drive continu momentum diagnost roll-out
europ measur date pick steam next quarter
meanwhil abbott first assay approv prepar launch
system domest kick multi-year upgrad cycl
manag believ allow sustain underli growth
page analyst certif import disclosur
see upsid potenti street estim abbott execut st jude
aler synergi opportun consensu current call adjust ep
repres healthi growth yoy fact repres fastest
project earn growth large-cap med-tech compani howev
back synergi st jude aler deal estim actual
impli underli growth base abbott busi view
rel unambiti number given compani histor track record figur
robust top line growth outlook outlin everi
underli growth ad anoth potenti manag initi
 accret estim prove conserv particularli case aler
assum signific reinvest busi littl underli improv
see realist pathway abbott earn closer year
compani report guggenheim secur llc estim
tax reform add element uncertainti abbott outlook believ
compani well posit net beneficiari bill becom law
past day compani still scrambl figur impact
differ provis bottom line tax rate
believ risk abbott could see effect rate increas result
reform howev abbott also stand benefit much compani sector
repatri nearli cash trap oversea end
after-tax basi estim abbott could bring back roughli provid
ampl flexibl off-set result tax headwind put context everi
increas compani tax rate would trim roughli ep howev
appli entir acceler share repurchas program abbott could
theoret boost earn manag could also use cash
pay debt weight averag interest rate pre-pay
debt could save abbott year realist would expect compani
pursu combin two strategi also leav dri powder
intern invest regardless approach manag ultim
choos howev believ ad balanc sheet flexibl posit abbott much
better peer weather near-term tax relat headwind
page analyst certif import disclosur
ad guggenheim best idea list price target model call
abbott gener top bottom line growth respect
solidli large-cap med-tech averag period
solid out-performance sinc june vs premium growth
outlook better reflect stock six month ago howev
share trade modestli large-cap group averag ntm ep vs
remain cheaper high growth peer like baxter
see potenti multipl expans abbott top line growth acceler
sentiment continu improv drive out-performance stock price
target base multipl previous forward
ntm ep estim signific upsid potenti target current level
reiter buy rate add guggenheim best idea list replac
page analyst certif import disclosur
abbott one largest healthcar compani world boast top line
lead franchis across medic devic diagnost nutrit establish
pharmaceut segment path get point long wind one
abbott reshuffl portfolio sever time past two decad recent
acquisit st jude medic aler dust settl deal
see abbott emerg premium grower within large-cap med-tech group
model call compani deliv top bottom line gain
respect compar averag peer yet
stock trade today modest premium group ntm ep vs
provid opportun rel multipl expans visibl st jude
aler integr improv growth acceler time med-tech investor
struggl find valu multipl high see attract
abbott share current trade ntm ep estim ntm
ebitda modestli large-cap med-tech averag
respect believ abbott above-averag growth profil peg
top bottom line respect vs group averag
warrant premium valuat price target previous
base multipl forward ntm ep estim signific
upsid potenti target current level assign abbott buy rate
downsid risk rate price target includ integr challeng relat
st jude aler acquisit pipelin setback and/or neg clinic result
impact abbott competit adopt key new product libr alin
etc fall short street expect
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
